栓塞治療市場－全球產業規模、佔有率、趨勢、機會和預測，按產品、適應症、程序、最終用戶、地區和競爭細分，2020 年至 2030 年

2024 年全球栓塞治療市場價值為 36.7 億美元，預計在預測期內將呈現令人印象深刻的成長，到 2030 年的複合年成長率為 8.35%。栓塞治療是一種微創治療方法，可選擇性地限制流向目標區域的血流。它是一種血管內手術，用於閉塞異常血管，有效控制或止血。在緊急嚴重出血病例中，栓塞治療已成為侵入性手術的可行替代方案。這種治療方法已獲得廣泛認可，並由全球各種臨床環境中的介入放射科醫生執行。栓塞治療的應用已大大擴展，特別是在尖端手術中，例如用於治療良性前列腺增生的前列腺動脈栓塞術 (PAE) 和用於減肥的胃動脈栓塞術 (GAE)。這兩種手術都是針對各自疾病的有效治療選擇。尤其是 PAE，每年在全球範圍內進行超過 800 例手術，以治療由 BPH 引起的下泌尿道症狀 (LUTS)。栓塞療法用於治療肌肉骨骼系統的慢性疼痛，包括骨關節炎、肩周炎和過度使用傷害。在全球範圍內，栓塞療法在治療子宮肌瘤的成功率約為85%。栓塞療法也用於治療特定類型的癌症，尤其是肝癌。

關鍵市場促進因素

目標患者群體不斷成長

主要市場挑戰

嚴格的規定

主要市場趨勢

增加收購與合作

目錄

第 1 章：產品概述

第2章：研究方法

第3章：執行摘要

第4章：顧客之聲

第5章：全球栓塞治療市場展望

• 市場規模和預測
  • 按價值
• 市場佔有率和預測
  • 依產品（栓塞劑、微導管）
  • 依適應症（腫瘤科、血管科、動脈瘤科、泌尿科、腎臟科）
  • 按程序（TACE、TARE）
  • 按最終使用者（醫院、診所、門診手術中心）
  • 按地區
  • 按公司分類（2024）
• 市場地圖

第6章：北美栓塞治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 北美：國家分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲栓塞治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 歐洲：國家分析
  • 德國
  • 英國
  • 義大利
  • 法國
  • 西班牙

第8章：亞太栓塞治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：南美栓塞治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲栓塞治療市場展望

• 市場規模和預測
• 市場佔有率和預測
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 11 章：市場動態

• 驅動程式
• 挑戰

第 12 章：市場趨勢與發展

• 合併與收購（如有）
• 產品發布（如有）
• 最新動態

第 13 章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 顧客的力量
• 替代產品的威脅

第 14 章：競爭格局

• Medtronic, PLC.
• Microport Scientific
• Boston Scientific Corporation
• Stryker Corporation
• Terumo Corporation
• Penumbra, Inc.
• Sirtex (CDH)
• Johnson & Johnson
• Abbott Laboratories Inc.
• Balt Group (Balt Extrusion SAS)

第 15 章：策略建議

第16章調查會社について,免責事項

Global Embolotherapy Market was valued at USD 3.67 Billion in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.35% through 2030. Embolotherapy is a minimally invasive treatment that selectively restricts blood flow to targeted areas. It is an endovascular procedure utilized to occlude abnormal blood vessels, effectively controlling or ceasing bleeding. In urgent cases of severe hemorrhage, Embolotherapy has emerged as a viable alternative to invasive surgery. This treatment option has gained widespread recognition and is performed globally by interventional radiologists in various clinical settings. The applications of Embolotherapy have expanded significantly, particularly in cutting-edge procedures such as prostatic artery embolization (PAE) for benign prostatic hyperplasia and gastric artery embolization (GAE) for weight loss. Both of these procedures serve as effective treatment options for their respective conditions. PAE, in particular, is performed worldwide in over 800 procedures annually to address lower urinary tract symptoms (LUTS) caused by BPH. Embolotherapy is employed in the management of chronic pain conditions in the musculoskeletal system, including osteoarthritis, frozen shoulder, and overuse injuries. Its application in treating uterine fibroids has shown a success rate of approximately 85% globally. It is utilized in the treatment of specific types of cancer, notably liver cancer.

Key Market Drivers

Growing Target Patient Population

Cardiovascular disease (CVD) is a significant target ailment, and its importance and high prevalence have made it a focal point for research into successful and effective treatments. For instance, in May 2023, a study in Stroke, the American Stroke Association's leading journal, detailed a groundbreaking in-utero surgery to treat a fetal vein of Galen malformation-a rare, life-threatening cerebral vascular disorder. This successful intervention highlights the expanding target patient population for embolotherapy, driven by advances in prenatal diagnostics and treatment. As awareness and early detection grow, demand for innovative embolization solutions in both pediatric and fetal care is expected to rise. In 2017, peripheral vascular diseases affected over 200 million individuals worldwide. According to the same source, the prevalence of these diseases rises with age, with a prevalence rate of over 20% in those aged 80 and above. The increasing demand for Embolotherapy devices will be driven by the notable success rate and low postoperative complication rate associated with Embolotherapy procedures, coupled with the rising incidence of liver cancer and hepatocellular cancer. Liver cancer ranks as the fifth most common cancer in men and the ninth most common cancer in women, with over 840,000 new cases diagnosed worldwide in 2018 (source: World Cancer Research Fund). The kidney cancer incidence rates in the United Kingdom have witnessed a significant 42% increase over the past decade, with males experiencing a 38% incidence rate and females a 44% rate.

Key Market Challenges

Stringent regulations

Artificial embolization devices, including permanent microspheres used as artificial emboli (AED), are classified as medical devices. These devices function by physically closing vessels and are regulated as Class II vascular and neurovascular embolization devices in the United States. In the European Union, they are classified as Class IIB bland embolization devices under the medical device directive MDD 93/42/EEC. PVA particles have been used for over 40 years as a comparison device, serving as the basis for approval or authorization of later next-generation items due to their demonstrated general embolization of vessels.

Key Market Trends

Increasing Acquisitions and Collaborations

Increasing acquisitions and collaborations can indeed contribute to an increased demand for embolotherapy in the future. Collaborative efforts within the healthcare industry often lead to enhanced research, development, accessibility, and awareness of medical procedures like embolotherapy. Collaborations between pharmaceutical companies, medical device manufacturers, and research institutions can accelerate the research and development of new and improved embolotherapy techniques, devices, and materials. This can lead to innovations that increase the effectiveness and safety of embolotherapy procedures. Acquisitions and collaborations bring together the expertise of different entities. This multidisciplinary approach can lead to the creation of comprehensive and integrated embolotherapy solutions that cater to diverse patient needs.

Key Market Players

• Medtronic, PLC
• Microport Scientific Corp
• Boston Scientific Corporation
• Stryker Corporation
• Terumo Corporation
• Penumbra, Inc.
• Sirtex (CDH)
• Johnson & Johnson
• Abbott Laboratories Inc.
• Balt Group (Balt Extrusion SAS

Report Scope:

In this report, the Global Embolotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Embolotherapy Market, By Product:

• Embolic Agents
  • Microspheres
  • Liquid Embolic Agents
  • Coil
• Microcatheters

Embolotherapy Market, By Indication:

• Oncology
• Vascular
• Aneurysm
• Urology
• Nephrology

Embolotherapy Market, By Procedure:

• TACE
• TARE

Embolotherapy Market, By End User:

• Hospital
• Clinics
• Ambulatory Surgery Centres

Embolotherapy Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Embolotherapy Market.

Available Customizations:

Global Embolotherapy market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validations
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Embolotherapy Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Embolic Agents, Microcatheters)
    • 5.2.1.1. By Embolic Agents (Microspheres, Liquid Embolic Agents, Coil)
  • 5.2.2. By Indication (Oncology, Vascular, Aneurysm, Urology, Nephrology)
  • 5.2.3. By Procedure (TACE, TARE)
  • 5.2.4. By End User (Hospital, Clinics, Ambulatory Surgery Centers)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Embolotherapy Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Indication
  • 6.2.3. By Procedure
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Embolotherapy Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Indication
      • 6.3.1.2.3. By Procedure
      • 6.3.1.2.4. By End User
  • 6.3.2. Canada Embolotherapy Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Indication
      • 6.3.2.2.3. By Procedure
      • 6.3.2.2.4. By End User
  • 6.3.3. Mexico Embolotherapy Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Indication
      • 6.3.3.2.3. By Procedure
      • 6.3.3.2.4. By End User

7. Europe Embolotherapy Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Indication
  • 7.2.3. By Procedure
  • 7.2.4. By End User
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Embolotherapy Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Indication
      • 7.3.1.2.3. By Procedure
      • 7.3.1.2.4. By End User
  • 7.3.2. United Kingdom Embolotherapy Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Indication
      • 7.3.2.2.3. By Procedure
      • 7.3.2.2.4. By End User
  • 7.3.3. Italy Embolotherapy Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Indication
      • 7.3.3.2.3. By Procedure
      • 7.3.3.2.4. By End User
  • 7.3.4. France Embolotherapy Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Indication
      • 7.3.4.2.3. By Procedure
      • 7.3.4.2.4. By End User
  • 7.3.5. Spain Embolotherapy Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Indication
      • 7.3.5.2.3. By Procedure
      • 7.3.5.2.4. By End User

8. Asia-Pacific Embolotherapy Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Indication
  • 8.2.3. By Procedure
  • 8.2.4. By End User
  • 8.2.5. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Embolotherapy Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Indication
      • 8.3.1.2.3. By Procedure
      • 8.3.1.2.4. By End User
  • 8.3.2. India Embolotherapy Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Indication
      • 8.3.2.2.3. By Procedure
      • 8.3.2.2.4. By End User
  • 8.3.3. Japan Embolotherapy Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Indication
      • 8.3.3.2.3. By Procedure
      • 8.3.3.2.4. By End User
  • 8.3.4. South Korea Embolotherapy Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Indication
      • 8.3.4.2.3. By Procedure
      • 8.3.4.2.4. By End User
  • 8.3.5. Australia Embolotherapy Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Indication
      • 8.3.5.2.3. By Procedure
      • 8.3.5.2.4. By End User

9. South America Embolotherapy Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Indication
  • 9.2.3. By Procedure
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Embolotherapy Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Indication
      • 9.3.1.2.3. By Procedure
      • 9.3.1.2.4. By End User
  • 9.3.2. Argentina Embolotherapy Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Indication
      • 9.3.2.2.3. By Procedure
      • 9.3.2.2.4. By End User
  • 9.3.3. Colombia Embolotherapy Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Indication
      • 9.3.3.2.3. By Procedure
      • 9.3.3.2.4. By End User

10. Middle East and Africa Embolotherapy Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Indication
  • 10.2.3. By Procedure
  • 10.2.4. By End User
  • 10.2.5. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Embolotherapy Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Indication
      • 10.3.1.2.3. By Procedure
      • 10.3.1.2.4. By End User
  • 10.3.2. Saudi Arabia Embolotherapy Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Indication
      • 10.3.2.2.3. By Procedure
      • 10.3.2.2.4. By End User
  • 10.3.3. UAE Embolotherapy Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Indication
      • 10.3.3.2.3. By Procedure
      • 10.3.3.2.4. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Medtronic, PLC.
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (As Reported)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. Microport Scientific
• 14.3. Boston Scientific Corporation
• 14.4. Stryker Corporation
• 14.5. Terumo Corporation
• 14.6. Penumbra, Inc.
• 14.7. Sirtex (CDH)
• 14.8. Johnson & Johnson
• 14.9. Abbott Laboratories Inc.
• 14.10. Balt Group (Balt Extrusion SAS)

15. Strategic Recommendations

16. About Us & Disclaimer